Investigational Drug Information for RIST4721
✉ Email this page to a colleague
What is the development status for investigational drug RIST4721?
RIST4721 is an investigational drug.
There have been 6 clinical trials for RIST4721.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 5th 2022.
The most common disease conditions in clinical trials are Psoriasis, Hidradenitis, and Blister. The leading clinical trial sponsors are Aristea Therapeutics, Inc. and [disabled in preview].
There are four US patents protecting this investigational drug and one hundred and seventeen international patents.
Summary for RIST4721
| US Patents | 4 |
| International Patents | 117 |
| US Patent Applications | 26 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2022-01-05) |
| Vendors | 16 |
Recent Clinical Trials for RIST4721
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) | Aristea Therapeutics, Inc. | Phase 2 |
| A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) | Aristea Therapeutics, Inc. | Phase 2 |
| A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) | Aristea Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for RIST4721
Top disease conditions for RIST4721
Top clinical trial sponsors for RIST4721
US Patents for RIST4721
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RIST4721 | ⤷ Sign Up | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Sign Up |
| RIST4721 | ⤷ Sign Up | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Sign Up |
| RIST4721 | ⤷ Sign Up | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | AstraZeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| RIST4721 | ⤷ Sign Up | Certain (25)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RIST4721
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RIST4721 | Argentina | AR099177 | 2034-01-24 | ⤷ Sign Up |
| RIST4721 | Australia | AU2015208932 | 2034-01-24 | ⤷ Sign Up |
| RIST4721 | Australia | AU2017200338 | 2034-01-24 | ⤷ Sign Up |
| RIST4721 | Australia | AU2018202956 | 2034-01-24 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
